The association between varying durations of previous vancomycin therapy and subsequent daptomycin success rates was evaluated in a subset of patients with methicillin-resistant Staphylococcus aureus bacteremia from the Cubicin® Outcomes Registry and Experience 2005-2009 (n=159). Previous vancomycin exposure did not adversely affect daptomycin outcomes; success rates were 81% in patients treated with first-line daptomycin and 89%, 83%, and 88%, respectively, in patients with 1-3days, 4-6days, and ≥7days of previous vancomycin exposure (P=0.5).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diagmicrobio.2015.06.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systemic Absorption of Oral and Rectal Vancomycin in a Critically Ill Patient: A Case Report.
Cureus
December 2024
Pulmonary and Critical Care Medicine, Rutgers New Jersey Medical School University Hospital, Newark, USA.
Enteral administration of vancomycin is the standard treatment for () colitis and is presumed to have no systemic absorption. In critically ill patients, however, especially with multi-organ failure, enteral absorption of vancomycin is unpredictable and can cause severe toxicity if it remains unrecognized. We therefore report a case of systemic absorption of enteric vancomycin in a patient with severe colitis.
View Article and Find Full Text PDFBilateral Preseptal Cellulitis and Upper Eyelid Abscess Without Predisposing Factors: A Case Report and Pathogenic Hypothesis.
Cureus
December 2024
Department of Oculo-Facial Plastic and Reconstructive Surgery, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IRN.
Bilateral preseptal cellulitis without accompanying sinusitis or skin trauma is uncommon. In this report, we present a case of bilateral preseptal cellulitis and an upper eyelid abscess in an otherwise healthy child. A nine-year-old girl presented with severe and progressive bilateral swelling of the upper lids that showed an unsatisfactory response to medical treatments (intravenous ceftazidime and vancomycin) and warranted a referral to our facility.
View Article and Find Full Text PDFIdentifying the Optimal Sampling Strategy for the Bayesian Estimation of Vancomycin AUC in Adult Hematologic Cancer Patients.
Clin Pharmacokinet
January 2025
Faculté de Pharmacie, Université de Montréal, Montréal, QC, Canada.
Background And Objective: The latest consensus recommends using the ratio between the area under the curve over 24 h (AUC) and minimal inhibitory concentration (MIC) as the therapeutic target for vancomycin in clinical practice, with a Bayesian approach and population pharmacokinetic (popPK) model being particularly recommended. While using both post-dose peak concentration (C) and pre-dose concentration (C) is more accurate than C alone, the optimal sampling strategy for estimating AUC is still unclear. The objective of this study was to determine the best sampling time(s) to estimate AUC using the Bayesian approach in these specific adult hematologic cancer patients.
View Article and Find Full Text PDFA Review of Vancomycin, Gentamicin, and Amikacin Population Pharmacokinetic Models in Neonates and Infants.
Clin Pharmacokinet
January 2025
Division of Medicines, Department of Pharmacy, Pharmacy Service, Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
Population pharmacokinetic (popPK) models are an essential tool when implementing therapeutic drug monitoring (TDM) and to overcome dosing challenges in neonates in clinical practice. Since vancomycin, gentamicin, and amikacin are among the most prescribed antibiotics for the neonatal population, we aimed to characterize the popPK models of these antibiotics and the covariates that may influence the pharmacokinetic parameters in neonates and infants with no previous pathologies. We searched the PubMed, Embase, Web of Science, and Scopus databases and the bibliographies of relevant articles from inception to the beginning of February 2024.
View Article and Find Full Text PDFClostridioides difficile infection and recurrence in cancer patients (CIRCA): a multicentre, international study.
Int J Infect Dis
January 2025
Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC, Australia; Department of Infectious Diseases and National Center for Infection, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, VIC, Australia.
Objectives: We aimed to describe the characteristics of Clostridioides difficile infection (CDI) in cancer patients, analysing risk factors for 90-day recurrence and attributable mortality.
Methods: Retrospective analysis on all CDI episodes from 2020 to 2022 in three Australian hospitals and one Spanish hospital. Logistic regression analyses were performed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!